Alcoholic liver disease/nonalcoholic fatty liver disease index: distinguishing alcoholic from nonalcoholic fatty liver disease

Eur J Gastroenterol Hepatol. 2013 Aug;25(8):899-904. doi: 10.1097/MEG.0b013e32835f0786.

Abstract

Objective: The alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) (ANI) scoring system was constructed as a response to a clinical need for avoiding the risks of liver biopsy in diagnosing the etiology of fatty liver disease. The aim of this study was to test the reliability of ANI as a noninvasive method to distinguish ALD from NAFLD.

Materials and methods: One hundred and thirty-five patients were classified into two groups, ALD and NAFLD, according to the pathohistological results. Parameters for ANI are aspartate aminotransferase, alanine aminotransferase, mean corpuscular volume, BMI, and sex. ANI was calculated using an online calculator, official site of Mayo Clinic.

Results: ANI was significantly higher in patients with ALD than NAFLD (P<0.01). The cutoff point of ANI is -0.66. ANI greater than -0.66 indicates ALD, whereas ANI less than -0.66 yields a higher probability of NAFLD with high specificity (96.7%) and sensitivity (84.1%). The mean corpuscular volume and aspartate aminotransferase/alanine aminotransferase ratio were higher, whereas BMI was lower in patients with ALD than in NAFLD (P<0.01).

Conclusion: The ANI scoring system may be used for the estimation of alcoholic origin of steatosis/steatohepatitis and may help in triaging patients for liver biopsy. ANI less than -0.66 indicates NAFLD, whereas ANI greater than -0.66 confirms the alcoholic etiology, but does not exclude the contribution of associated factors toward the development of fatty liver in a Serbian population.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Alanine Transaminase / blood
  • Aspartate Aminotransferases / blood
  • Biomarkers / blood
  • Biopsy
  • Body Mass Index
  • Chi-Square Distribution
  • Clinical Enzyme Tests
  • Decision Support Techniques*
  • Diagnosis, Differential
  • Erythrocyte Indices
  • Fatty Liver / blood
  • Fatty Liver / diagnosis*
  • Fatty Liver / pathology
  • Fatty Liver, Alcoholic / blood
  • Fatty Liver, Alcoholic / diagnosis*
  • Fatty Liver, Alcoholic / pathology
  • Female
  • Humans
  • Liver / pathology
  • Logistic Models
  • Male
  • Middle Aged
  • Nomograms
  • Non-alcoholic Fatty Liver Disease
  • Predictive Value of Tests
  • Prognosis
  • Reproducibility of Results
  • Retrospective Studies
  • Risk Factors
  • Serbia
  • Sex Factors

Substances

  • Biomarkers
  • Aspartate Aminotransferases
  • Alanine Transaminase